News and Trends 15 Apr 2020 Healx Deploys AI Drug Discovery Technology Against Rare Nerve Disease The AI-driven drug repurposing company Healx has teamed up with the global Children’s Tumor Foundation (CTF) to develop new treatments for the genetic disease neurofibromatosis type 1, right after the FDA approved the first-ever drug for the condition. In the collaboration, the UK biotech will use its AI-driven pharmacology expertise to speed a candidate drug […] April 15, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2020 UK-US Initiative to Screen Drugs Using AI for Coronavirus Treatments The UK company Exscientia will use its AI-driven drug discovery platform to examine a collection of 15,000 potential coronavirus disease treatments in collaboration with the US research institute Calibr and the non-profit synchrotron company Diamond Light Source. The team’s huge collection of drug molecules will be provided by Calibr, part of the US medical institute […] April 3, 2020 - 4 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
Startup Scout 14 Feb 2020 Novadiscovery Carries out Clinical Trials using AI and Simulations Novadiscovery, based in Lyon, France, is developing AI-based simulation technology to predict clinical trial outcomes and cut their running costs. Mission: To predict the outcomes of clinical trials in silico using a combination of artificial intelligence (AI) and computational models of the biology underlying the disease. Clinical trials cost the healthcare industry billions of euros […] February 14, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2020 French Partnership Deploys AI for Antibody Drug Discovery French companies OSE Immunotherapeutics and MAbSilico are teaming up to drive the discovery of new antibody drugs using artificial intelligence. The three-year partnership will use artificial intelligence, or AI, in six programs designed to accelerate the development of therapeutic monoclonal antibodies (mAbs) that can target cancer and autoimmune diseases. AI can improve the efficiency of […] February 13, 2020 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 4 Feb 2020 Swiss Biotech Raises €16M to Treat Autism Spectrum Disorder Stalicla has bagged €16.3M in a Series A round to test drugs repurposed using AI for the treatment of autism spectrum disorder in phase I. The round consists of a recent €7M (CHF 7.7M) closing and an initial first tranche of €9.3M (CHF 10M) raised last year. The investors in the latest closing were not […] February 4, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2020 AI-Designed Drug Enters Phase I to Treat OCD A drug designed by the UK firm Exscientia using AI-powered software has entered into a phase I clinical trial for the treatment of obsessive-compulsive disorder, commonly known as OCD. The clinical development of the drug will be carried out by Sumitomo Dainippon Pharma, Exscientia’s Japanese collaborator. The drug took just 12 months to get to […] January 31, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Nov 2019 UK Scientists Speed up Brain Cancer Diagnosis with AI A technique combining a blood test with artificial intelligence (AI), developed by the UK company ClinSpec Diagnostics, could help to prioritize which patients need to be scanned for brain cancer. A team led by researchers at the University of Strathclyde and the University of Edinburgh, UK, trialed the technology on blood samples from 400 people […] November 5, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2019 AI-Driven Antibiotic Susceptibility Test Launched in Austria Ares Genetics, an Austrian subsidiary of the German Curetis Group, has launched an early access program for its AI-driven antibiotic susceptibility test. The company, which focuses on molecular diagnostics, has a large, regularly updated database of genetic information on disease-causing microbes including strains showing antimicrobial resistance. The new test uses high-resolution sequencing to gain genetic […] October 28, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Startup Scout 25 Oct 2019 This UK AI Tool Researches Diseases for Drug Discovery Companies The Manchester-based company Biorelate is developing artificial intelligence (AI) technology that can collect biological data from the internet and speed up the drug discovery process. Mission: Develop AI technology that trawls the web for disease and drug data and collects it together like researchers would do manually in drug discovery. Biorelate’s product is able to […] October 25, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2019 British AI Firm Gets €9M Boost to Develop Drug-Discovery Tech London-based LabGenius has secured €8.9M in Series A funding, which the company plans to use to scale up its AI- and robotics-based drug development technology. LabGenius focuses on developing protein-based therapeutics using its ‘robot scientist’ EVA. “By transforming how these drugs are discovered, we have a shot at improving the lives of countless people,” said […] October 24, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 23 Oct 2019 Channeling the Power of AI into Personalizing Medicine Artificial intelligence has been much discussed of late, but will it really help us solve important problems like how to bring personalized medicine to as many patients as possible? Kate Hilyard, COO of Healx in Cambridge in the UK, believes it can. Getting a drug to clinical trials currently requires a large investment of both […] October 23, 2019 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2019 UK Firm Raises €51M to Repurpose Drugs for Rare Diseases Using AI The Cambridge-based artificial intelligence company Healx has raised a Series B round of €50.8M to launch an AI tool that reduces the time it takes to develop treatments for rare diseases by five years. The Series B round was led by the UK VC firm Atomico and includes the returning investor Jonathan Milner, the founder […] October 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email